Single intravitreal ranibizumab injection in eyes with acute non‐arteritic anterior ischaemic optic neuropathy

Abstract

Background:The aim was to evaluate the effect of a single intravitreal ranibizumab injection in eyes with non-arteritic anterior ischaemic optic neuropathy. Methods: Four eyes of four patients comprised the study group. In addition to a standard ocular examination, visual field testing and retinal nerve fibre layer thickness analysis were performed prior to injection and one and three months after the injection. Results: Mean time between visual loss and the intravitreal injection was 7.8 days (range, 2-15 days). The mean age of patients was 58.2 years (range, 45-63 years). After a single dose of ranibizumab injection, all patients experienced a visual gain. Mean visual acuity (VA) was 1.15 Ϯ 0.26 logMar before the injection and improved to 0.37 Ϯ 0.09 logMar at the third post-injection month. The mean retinal nerve fibre layer thickness measured with spectral domain optical coherence tomography significantly decreased after the injection in all eyes. No complication related to the injections was observed during the following three months. Conclusion: Intravitreal ranibizumab injection may be a treatment option in eyes with non-arteritic anterior ischaemic optic neuropathy and a short disease history.

Macular Evaluation wıth Spectral Domain Type Optic Coherence Tomography in Eyes with Acute Nonarteritic Ischemic Optic Neuropathy at the Presentation Visit

“…We previously suggested that one of the reasons to administer intravitreal antiVEGF agents in acute NAION is the presence of subretinal fluid, as anti VEGF agents may theoratically alleviate the subretinal fluid and thereby help the improvement of visual acuity [16-18]. However, the use of intravitreal anti VEGF’s is highly controversial in eyes with a NAİON and Rootman et al .…”

An unusual presentation of nonarteritic ischemic optic neuropathy with subretinal fluid treated with intravitreal bevacizumab

“…in their study of four eyes showed visual improvement after injecting intravitreal ranibizumab for NAION. [ 5 ] Pece et al . and Arnold and Hepler in their study, on the other hand, showed no visual improvement in vision after intravitreal ranibizumab.…”

Single Intravitreal Aflibercept Injection for Unilateral Acute Nonarteritic Ischemic Optic Neuropathy

“…Our preliminary report about four eyes treated with 0.5 mg intravitreal ranibizumab showed promising results after a follow-up of three months. All of our patients experienced some degree of visual gain [ 11 ]. We conducted another retrospective clinical analysis on 17 eyes of 16 patients who experienced a visual loss with a duration of 15 days or less who received 0.5 mg intravitreal ranibizumab injection.…”